1. Home
  2. INGN vs SABS Comparison

INGN vs SABS Comparison

Compare INGN & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inogen Inc

INGN

Inogen Inc

HOLD

Current Price

$6.95

Market Cap

172.4M

Sector

Health Care

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.48

Market Cap

201.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INGN
SABS
Founded
2001
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
172.4M
201.4M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
INGN
SABS
Price
$6.95
$3.48
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$11.25
$10.75
AVG Volume (30 Days)
286.0K
352.8K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
43.42
N/A
EPS
N/A
N/A
Revenue
$348,668,000.00
N/A
Revenue This Year
$8.03
N/A
Revenue Next Year
$7.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.86
N/A
52 Week Low
$5.34
$1.54
52 Week High
$9.13
$6.60

Technical Indicators

Market Signals
Indicator
INGN
SABS
Relative Strength Index (RSI) 55.59 37.60
Support Level $6.59 $3.43
Resistance Level $7.46 $4.11
Average True Range (ATR) 0.36 0.20
MACD 0.04 -0.04
Stochastic Oscillator 53.07 5.22

Price Performance

Historical Comparison
INGN
SABS

About INGN Inogen Inc

Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: